Patient Capital provides an overview about the pivotal role venture capital and venture backed companies play in the development of novel medical innovation. The publication provides an overview of key medical innovations that can be traced back to venture capital funding and real life examples of how venture capital investment has resulted in better technology and saving/improving lives.

Executive Summary

Patient Capital: How Venture Capital Investment Drives Revolutionary Medical Innovation demonstrates that many of the nation’s most innovative medical breakthroughs have been brought to market by billions of dollars of venture capital investment in life sciences companies. The economic impact and medical contributions of these life sciences companies have been enormous.

The revolutionary medical breakthroughs produced by venture capital backed companies such as Amgen, Genentech, Genzyme, Gilead Sciences, Kyphon, Intuitive Surgical, and Scimed Life Systems, along with hundreds of smaller innovative life sciences companies, amount to highly tangible and valuable improvements to the U.S. economy and to people’s lives. Today, small venture backed companies often serve as the research and development (R&D) pipeline for the larger life sciences corporations who seek to acquire the most promising innovations. Whether these emerging companies someday grow to the size of a For tune 500 corporation or are acquired for their groundbreaking products, they all rely on the venture capital industry to get their start.

About the Study

This study was prepared by Michaela Platzer, president, Content First, LLC, a public policy research services firm based in Washington, DC. The purpose of the study is to provide policy makers, the press, and the public with an overview about the pivotal role venture capital backed companies have played, and will continue to play, in the development of novel medical innovation from new biotechnology therapies to revolutionary medical devices. These innovative medical technologies affect virtually all Americans.

The study is part of the National Venture Capital Association’s (NVCA) Medical Industry Group (MIG) public outreach program aimed at collecting and disseminating information about the important role that life sciences venture investing plays in driving revolutionary medical innovation. NVCA’s MIG focuses on addressing the unique needs of venture backed companies investing in the life sciences industry.

Download Patient Capital: How Venture Capital Investment Drives Revolutionary Medical Innovation

PDF format, .7.5MB, 24Pages. Provided by NVCA.

Patient Capital: How Venture Capital Investment Drives Revolutionary Medical Innovation

2 Executive Summary

6 Section I
Venture Capitalists Are Committed to Investing In and Growing the Life Sciences Sector

9 Section II
Venture Capital Saves Lives and Money by Funding Revolutionary Medical Breakthroughs

11 Section III
Venture Capital Backed Life Sciences Investment Depends Upon a Predictable and Efficient Path Within the Regulatory Environment

13 Section IV
Venture Capital Contributes to Medical Innovation
13 The Heart Attack Drug, Integrilin
13 Blood Glucose Self-Monitoring
14 Minimally Invasive Breast Biopsy
14 Osteoporosis

16 Conclusion: Venture Capital Drives the Next Generation of Cures
17 Venture Capital 101: What Is Venture Capital?
19 About the Author and the National Venture Capital Association
20 Endnotes

About the Author and the National Venture Capital Association

Michaela Platzer, Content First, LLC

Michaela Platzer is president of Content First, LLC, a full-service public policy research services firm in Washington, DC that utilizes a unique process of melding solid research and analysis with presentation and communication to bring advocacy data, industry statistics, and policy research to life for trade associations, businesses, law firms, consulting firms, and the public affairs community.

Michaela brings more than 20 years of public policy research experience to her firm as vice president, research and policy analysis for the American Electronics Association (AeA), manager, European affairs, for the U.S. Chamber of Commerce, and international economist for the Embassy of the Republic of South Korea. She has authored numerous publications, including the NVCA reports, Venture Impact: The Economic Importance of Venture Capital Backed Companies to the U.S. Economy and American Made: The Impact of Immigrant Entrepreneurs and Professionals on U.S. Competitiveness, as well as economic and policy reports for the Transatlantic Business Dialogue, the Representative of German Industry and Trade, the Organization for International Investment, the U.S. Chamber of Commerce, and the Korea-U.S. Business Council. Other publications authored by Michaela include AeA’s Cyberstates, Cybernation, and CyberEducation reports and the U.S. Chamber’s policy studies on the European internal market program. Michaela holds an M.A. from the Johns Hopkins School of Advanced International Studies and a B.A. from the University of California.

For more information about Content First, please visit www.contentfirst.com.

National Venture Capital Association

The National Venture Capital Association (NVCA) represents approximately 480 venture capital and private equity firms. NVCA’s mission is to foster greater understanding of the importance of venture capital to the U.S. economy and support entrepreneurial activity and innovation. According to a newly released study by Global Insight, venture backed companies provided 10.4 million U.S. jobs and $2.3 trillion in revenue in 2006.

NVCA represents the public policy interests of the venture capital community, strives to maintain high professional standards, provides reliable industry data, sponsors professional development, and facilitates interaction among its members.

Comments (0)

Show/Hide comments

Name

Email

Website

Title

Comment

smaller | bigger

Add Comment